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Abstract Endothelial cells regulate vascular tone by releas-
ing various contracting and relaxing factors including nitric
oxide (NO), arachidonic acid metabolites (derived from
cyclooxygenases, lipoxygenases, and cytochrome P450
monooxygenases), reactive oxygen species, and vasoactive
peptides. Additionally, another pathway associated with the
hyperpolarization of the underlying smooth muscle cells plays
a predominant role in resistance arteries. Endothelial
dysfunction is a multifaceted disorder, which has been
associated with hypertension of diverse etiologies, involving
not only alterations of the L-arginine NO-synthase–soluble
guanylyl cyclase pathway but also reduced endothelium-
dependent hyperpolarizations and enhanced production of
contracting factors, particularly vasoconstrictor prostanoids.
This brief review highlights these different endothelial path-
ways as potential drug targets for novel treatments in
hypertension and the associated endothelial dysfunction and
end-organ damage.
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Introduction
Furchgott and Zawadzki [1] described the obligatory role of
the endothelial cells during relaxations of the isolated rabbit
aorta to acetylcholine and demonstrated the transfer of a
vasodilator substance termed “endothelium-derived relax-
ing factor.” This factor was identified as nitric oxide (NO)
and became a major player in physiology, pharmacology,
and pathophysiology [2]. Over the years, however, it became
obvious that NO could not explain all endothelium-
dependent responses, and that endothelium-dependent relax-
ations can be caused by hyperpolarizations of the underlying
vascular smooth muscle cells that are not due to
endothelium-derived NO but rather to endothelium-derived
hyperpolarizing factors (EDHFs) [3]. Another important
aspect of endothelium-dependent control of vasomotor tone
emerged with the demonstrations that endothelial cells can
produce contracting factors, particularly vasoconstrictor
prostanoids [4, 5]. It has thus become obvious that no single
factor or mechanism is responsible for all endothelium-
dependent responses, and that their modulation by age and
disease leads to endothelial dysfunction, which has become a
hallmark of vascular disease and a predictor of major
cardiovascular events [5]. This brief review presents some
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recent information concerning the multiplicity of endothelium-
dependent signals and their possible contribution to the
control of vascular tone in health and its derangement in
hypertension.
Endothelium-derived Nitric Oxide
A common denominator in hypertension, regardless of its
etiology (essential, renovascular, malignant, or preeclamptic),
is endothelial dysfunction, which involves reduced produc-
tion, decreased bioavailability, and/or impaired cellular effects
of NO [6]. Therefore, various potential therapeutic targets
have been identified all along the L-arginine–NO-synthase–
soluble guanylyl cyclase pathway (Fig. 1).
When L-arginine is deficient, endothelial NO synthase
(eNOS) can generate both superoxide anions and NO,
leading to the detrimental production of peroxynitrite. It is
still a matter of debate whether L-arginine deficiency
occurs in vivo to limit the production of NO by eNOS,
but L-arginine supplementation improves endothelial dys-
function in hypercholesterolemia and hypertension [7]. In
addition, endogenous analogues such as asymmetric
dimethyl-L-arginine (ADMA) can compete with L-arginine
for its specific membrane transporter and also directly for
access to eNOS, where ADMA acts as an inhibitor. The
plasma concentration of ADMA represents an independent
predictor for all causes of cardiovascular mortality. Free
dimethylarginines are the products of proteolytic degrada-
tion of arginine-methylated proteins by protein arginine
N-methyltransferase type I (PRMT-I). In endothelial cells,
ADMA is metabolized mainly by dimethylarginine
dimethylaminohydrolase-2 (DDAH-2). During angiotensin
II administration and oxidative stress, the observed elevation
in ADMA levels is associated with an increase in the activity
of PRMT and a decrease in the activity of DDAH. Silencing
the DDAH-2 gene impairs endothelium-dependent relaxa-
tion and NO production. Therefore, the inhibition of PRMT-I
and the activation or enhanced expression of DDAH-2 could
be beneficial in treating cardiovascular disease [7].
Endothelial cells express arginases (with arginase-2 being
the predominant isoform), which metabolize L-arginine to L-
ornithine and urea. Arginase-2 competes with eNOS for
substrate, and its expression and activity are enhanced in
cardiovascular diseases, perhaps because of increased oxida-
tive stress. In animal models, inhibition and gene deletion of
arginase-2 improve endothelium-dependent relaxations and
the vascular production of NO, prevent the development of
hypertension, and decrease the generation of endothelial
reactive oxygen species (ROS) and the formation of
atherosclerotic plaques [8]. Arginase-2 may therefore repre-
sent a promising novel therapeutic target that could reverse
vascular dysfunction in hypertension.
Reduced expression of eNOS could be responsible for
decreased NO production, but in most situations where
endothelial dysfunction is encountered, the expression of
eNOS is increased paradoxically, most likely because
oxidative stress generates hydrogen peroxide, which
increases the expression of the enzyme. Endothelial
dysfunction associated with this increased expression of
eNOS shows that the ability to generate NO is reduced or
its bioavailability is decreased. The reduction in NO
generation can be attributed to eNOS uncoupling, whereby
the enzyme itself is a source of superoxide anions and a
cause of endothelial dysfunction [9].
Tetrahydrobiopterin (BH4) is an essential cofactor that
critically controls the assembly and activity of eNOS.
Decreased endothelial levels of BH4 are responsible not
only for a reduction in NO production but also for the
uncoupling of eNOS. BH4 is highly susceptible to oxidation
by peroxynitrite, forming BH2 and ultimately biopterin.
BH4 is synthesized de novo from guanosine triphosphate
Fig. 1 Nitric oxide (NO) synthase, lipoxygenase (LO), and cytochrome
P450 monooxygenase (CYP) pathways and responses mediated by
endothelium-derived hyperpolarizing factors (EDHFs): potential sites of
therapeutic intervention for hypertension. The circled numbers indicate
potential sites of intervention: 1, L-arginine supplementation. 2,
Inhibition of protein arginine N-methyltransferase type I (PRMT-I) to
prevent the formation of asymmetric dimethyl-L-arginine (ADMA).
3, Increased expression and/or activity of dimethylarginine
dimethylaminohydrolase-2 (DDAH-2) to facilitate ADMA catabo-
lism. 4, Inhibition of arginase-2 to prevent L-arginine metabolism. 5,
Increased expression and/or activity of endothelial nitric oxide
synthase (eNOS). 6, Design of drugs that evoke endothelium-
dependent relaxations. 7, Enhanced expression and/or activity of
guanosine triphosphate cyclohydrolase (GTPCH), the rate-limiting
enzyme for tetrahydrobiopterin (BH4) synthesis, or direct supple-
mentation with BH4 or its precursor sepiapterin. 8, Enhanced
expression and/or activity of dihydrofolate reductase (DHFR),
involved in BH4 regeneration. 9, Scavengers of reactive oxygen
species (ROS), antioxidants. 10, Inhibition of the activity and/or
expression of enzymes that generate ROS, such as NAD(P)H
oxidases (NOX), cyclooxygenases (COX), lipoxygenases (LOX),
or cytochrome P450 monooxygenases (P450). 11, Enhanced expres-
sion and/or activity of enzymes that metabolize ROS, such as
superoxide dismutase (SOD) or catalase (or, alternatively, synthesis
of mimetics). 12, Stimulation of soluble guanylyl cyclase (sGC). 13,
Activation of sGC. 14, Inhibition of phosphodiesterase-5 (PDE-5).
15, Inhibition of soluble epoxide hydrolase (sEH) to suppress
degradation of epoxyeicosatrienoic acids (EETs). 16, Opening
calcium-activated potassium channels of small, intermediate, or large
conductance (SKCa, IKCa, BKCa). 17, Opening transient receptor
potential channels (TRP). AA—arachidonic acid; BH2—dihydrobiopterin;
CAT-1—cationic amino acid transporters; CaV—voltage-activated
calcium channel; cGMP—cyclic guanosine monophosphate;
DHETs—dihydroxyeicosatrienoic acids, EC—endothelial cell;
FAD—flavin adenine dinucleotide; FMN—flavin mononucleo-
tide; HEETA—hydroxy-epoxyeicosatrienoic acid; 12-HETE—12-
hydroxyeicosatetraenoic acid; KIR—inward rectifying potassium
channel; MEGJ—myoendothelial gap junction; O2
•−—superoxide anion;
ONOO−—peroxynitrite; PKG—protein kinase G; THETA, trihydrox-
yeicosatrienoic acid; VSMC—vascular smooth muscle cell
b
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(GTP) following a series of enzymatic reactions, whereby
GTP-cyclohydrolase I (GTPCH-I) is the first and rate-
limiting step. An alternative pathway for BH4 synthesis, the
“salvage pathway,” involves the formation of sepiapterin
and its subsequent reduction in dihydrobiopterin (BH2),
which is further reduced by dihydrofolate reductase
(DHFR) to form BH4. Following oxidation, BH4 can be
regenerated by either DHFR or dihydropteridine reductase.
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Increased vascular homocysteine is a risk factor for
atherosclerosis; it leads to endothelial dysfunction, and
some of its effects may be mediated by inhibition of BH4 de
novo synthesis [10]. Direct supplementation with BH4 or its
precursor, sepiapterin, improves endothelial function in
animals, in smokers, and in patients with hypertension,
diabetes, hypercholesterolemia, or coronary disease. En-
hancing the expression or the activity of GTPCH-I (for de
novo BH4 synthesis) or of DHFR (for BH4 regeneration)
may prevent the occurrence of endothelial dysfunction.
Alternative strategies include supplementation with folic
acid, which enhances the binding affinity of BH4 to NOS,
stabilizes BH4 chemically, and stimulates DHFR. Prevent-
ing peroxynitrite formation (and therefore BH4 oxidation)
or facilitating the recycling of BH4 regeneration with
vitamin C can also be considered [9].
Inhibition or deletion of eNOS causes accelerated
atherosclerosis in rabbits and mice. However, apoE−/− mice
overexpressing eNOS develop larger atherosclerotic lesions
than control apoE−/− mice. Again, this paradox is explained
best by the peroxynitrite-dependent uncoupling of eNOS
and the subsequent production of superoxide anions.
However, eNOS uncoupling can be prevented if the
upregulation of eNOS is associated with an increased
availability of essential cofactors such as BH4. Compounds
such as AVE9488 and AVE3085, which enhance eNOS
promoter activity, possess such a coordinated activity and
validate the concept that enhanced transcriptional expres-
sion of eNOS can be beneficial in preventing cardiovascu-
lar diseases [11•].
Besides preventing eNOS uncoupling, other therapeutic
strategies can be designed to restore proper NO levels.
These include drugs that stimulate the release of NO by
endothelial eNOS, NO donor drugs, antioxidant com-
pounds, drugs that boost the antioxidant defense mecha-
nisms, and inhibitors of enzymes involved in the generation
of ROS.
Some antihypertensive drugs—for instance, nebivolol,
various dihydropyridines, angiotensin-converting enzyme
(ACE) inhibitors, angiotensin (AT1) receptor blockers
(ARBs), and possibly renin inhibitors—can directly or
indirectly stimulate the release of endothelial NO. Addition-
ally, chronic treatments with ACE inhibitors, ARBs, or renin
inhibitors increase eNOS expression. Although chronic
treatment with ACE inhibitors or ARBs consistently
improves endothelial function in animal models of hyper-
tension, variable effects have been reported in hypertensive
patients, possibly because of the multifactorial etiology of
essential hypertension or differences in the experimental
clinical protocols [12].
Besides uncoupled eNOS, NAD(P)H oxidase is a
predominant source of excess ROS in the vascular wall in
essential hypertension [13]. Thus, inactivation of superox-
ide anions with superoxide dismutase mimetics or scav-
enging of ROS with antioxidants seems an obvious way of
increasing NO bioavailability. Such strategies have been
successful in various animal models of hypertension.
However, large clinical trials of chronic antioxidant therapy
in hypertensive patients have not produced major reduc-
tions in arterial blood pressure and did not improve the
associated morbidity and mortality, with the possible
exception of chronic intake of polyphenols (present in red
wine, fruit, and vegetables) [14]. The reasons underlying
these failures are not clear. Synthetic inhibitors of NAD(P)H
oxidase have been proposed as an alternative, but it is
still uncertain which isoforms of NAD(P)H should be
inhibited, and the available inhibitors are neither specific
nor potent enough, and they have poor pharmacokinetic
properties [15••].
Activation of the renin-angiotensin system with subse-
quent stimulation of AT1 receptors is a major stimulus for
NAD(P)H oxidase and production of ROS in both animal
models and in hypertensive patients [6]. Preventing ROS
generation—by deleting a subunit of NAD(P)H oxidase, for
instance—causes resistance to angiotensin II–induced hy-
pertension and markedly reduces the associated endothelial
generation of superoxide anions [16]. In rat models of
hypertension, ACE inhibitors and ARBs decrease the
generation of superoxide anions, diminish the amplitude
of endothelium-dependent contractions, and restore the
amplitude of both NO-mediated and EDHF-mediated
endothelium-dependent relaxations [17]. In addition to
lowering lipids, statins also decrease the expression of
NAD(P)H subunits and increase eNOS expression, improv-
ing the balance between NO and ROS. These endothelial
effects may contribute to the pleiotropic effects of these
compounds.
To date, the clinical use of NO donor drugs is limited
by the development of nitrate tolerance, a complex
multifactorial phenomenon associated with the generation
of oxidative stress and endothelial dysfunction [18]. New
chemical classes of NO donors, some of which can
spontaneously release NO, have been synthesized and
may have a therapeutic interest beyond the treatment of
coronary disease and heart failure. Hybrid compounds
possessing dual activity also have been synthesized.
Earlier compounds such as nicorandil (an organic nitrate
that opens potassium channels) and nipradilol (a nonse-
lective adrenoceptor blocker with NO-releasing proper-
ties) are still predominantly prescribed for angina and
glaucoma, respectively. New hybrid compounds including
NO-releasing antiadrenergic drugs, NO-releasing dihydro-
pyridines, NO-releasing statins, NO-releasing ARBs, and
NO-releasing ACE inhibitors are of therapeutic interest
for treating hypertension and associated end-organ damage
[19•].
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The regulation of nitric oxide bioactivity can also be
achieved by modulating soluble guanylyl cyclase, the main
physiological target of NO, or the half-life of the signaling
molecule, cGMP, which is readily hydrolyzed by phospho-
diesterases. Two different classes of compounds—stimulators
and activators—interact with soluble guanylyl cyclase [20•,
21•]. The former stimulate the enzyme in an NO-
independent but heme-dependent manner; acting as allosteric
modulators, they enhance NO-dependent cGMP production.
By contrast, activators of soluble guanylyl cyclase target the
enzyme when its heme is oxidized and no longer responsive
to NO. Both activators and stimulators of soluble guanylyl
cyclase are potent vasodilators and inhibitors of platelet
aggregation. The stimulators are currently undergoing
clinical trials in acute decompensated heart failure and
peripheral artery occlusive disease, and the activators are
being evaluated in pulmonary hypertension. Potential thera-
peutic indications of these new compounds include hyper-
tension, myocardial ischemia, erectile dysfunction,
atherosclerosis, and thrombosis [20•, 21•].
Phosphodiesterase 5 (PDE-5) was the first identified
selective cGMP esterase in the cardiovascular system and is
the major isoform involved in the hydrolysis of the cGMP
pools generated by the activation of soluble guanylyl
cyclase. Specific PDE-5 inhibitors are currently prescribed
for erectile dysfunction but, in the future, their therapeutic
indications may also include pulmonary hypertension, heart
failure, and essential hypertension [22].
Endothelium-dependent Hyperpolarizations
EDHF-mediated responses can provide a vasodilator
reserve in hypertension and can compensate, at least
temporarily, for endothelial dysfunction due to compro-
mised synthesis or availability of NO [3]. However,
reduced endothelium-dependent hyperpolarizations also
can contribute to arterial dysfunction in animal and human
cardiovascular disease, especially hypertension and diabe-
tes [3]. In any case, whether EDHF-mediated responses are
diminished or conserved, it is still possible to pharmaco-
logically stimulate the endothelial cells in order to inhibit
the underlying vascular smooth muscle, thereby improving
vasodilator responses and lowering arterial blood pressure
in experimental and human hypertension or reversing
endothelial dysfunction in diabetes [23, 24, 25••]. There
are presumably a variety of structurally very distinct factors
or pathways that can produce EDHF-mediated dilatations.
Indeed, residual NO, products of the metabolism of
arachidonic acid (including prostacyclin), hydrogen perox-
ide, potassium ions, and C-natriuretic peptide all have been
proposed as EDHFs. In addition, a nonchemical EDHF-
signaling pathway involves transfer of negative charges
from the endothelium to the smooth muscle via gap
junctions [3]. In the case of EDHF pathways involving K+
ions and electrical gap-junctional myoendothelial coupling,
activation of endothelial calcium-activated potassium (KCa)
channels initiates the dilator response in many preparations
by triggering hyperpolarization and K+ release (Fig. 1). The
in vivo relevance of endothelial KCa channels is indicated
by the severely impaired EDHF-mediated responses and the
elevated arterial blood pressure in mice deficient of
endothelial intermediate-conductance channels (IKCa,
KCa3.1) and small-conductance channels (SKCa, KCa2.3)
[24, 26••]. Moreover, selective openers of endothelial IKCa
and SKCa, NS-309 [23] and SKA-31 [27], may be of
therapeutic use in cardiovascular disease because they have
been shown to improve endothelial function in type 2
diabetes [23] and to lower blood pressure in mice with
angiotensin II–induced hypertension [27].
Hydrogen peroxide, another putative EDHF, may
amplify this IKCa- and SKCa-driven EDHF system by
facilitating inositol-trisphosphate (IP3)-mediated Ca
2+ re-
lease and thus enhancing endothelial Ca2+ signaling [3, 28],
thereby further stimulating the two channels. However, the
well-known harmful effects of hydrogen peroxide make it
questionable whether pharmacologic enhancement of its
production could be a strategy to lower arterial blood
pressure [29].
Of the products of the metabolism of arachidonic acid,
eicosanoids generated by lipoxygenase (LO) and cytochrome-
P450 (CYP) monooxygenase pathways are the most likely
candidates as diffusible endothelium-derived relaxing factors
[30•]. LO and CYP pathways are complex and yield many
metabolites with diverse effects on vascular tone. The
mechanisms by which LO-derived and CYP-derived eicosa-
noids produce vasodilatation include the activation of potas-
sium channels (Ca2+-activated large-conductance [BKCa]
channels and small-conductance [SKCa-like] channels) leading
to hyperpolarization, closure of L-type Ca2+ channels, and
thus relaxation (Fig. 1). Because of this ability of LO-derived
and CYP-derived eicosanoids to both hyperpolarize and relax
smooth muscle, their vasodilator activity has been linked to
EDHF-mediated responses in several vascular beds [3, 30•].
The endothelium expresses the three major LO isoforms:
5-LO, 12-LO, and 15-LO. The products of 12-LO and 15-
LO cause dilatation, whereas leukotrienes generated by 5-
LO are associated with vasoconstriction [30•]. The 12-LO
product, 12(S)-HETE, produces vasodilatation by activat-
ing BKCa channels and thus hyperpolarizing the vascular
smooth muscle cells, whereas HEETA and THETA,
generated by 15-LO, open SKCa-like channels [30•]. The
role in vivo of these LO products as endothelium-derived
relaxing factors is uncertain. Pharmacologic inhibition with
BW755C or genetic knockdown of 12/15-LO had no effect
on arterial blood pressure [30•], but gene transfer of human
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15-LO-1 enhanced the hypotension caused by acetylcholine
[30•]. In contrast, LO inhibitors reduce angiotensin-II–
induced hypertension [30•], and inhibition of 12/15-LO by
baicalein and derivatives has beneficial effects in experi-
mental ischemic stroke [30•]. Considering the blood
pressure lowering effects and cerebrovascular protective
effects of LO inhibitors on one hand, and the beneficial
effects on arterial blood pressure of 15-LO overexpression
on the other hand, it is difficult to decide on the potential
benefit of stimulating the production of LO-derived
endothelium-derived relaxing factors in hypertension. With
respect to inflammatory responses and atherosclerosis, the
polymorphisms in the human 12/15-LO gene (ALOX15)
lead to either enhanced enzyme activity with a lowered risk
of coronary artery disease [31] or to impaired enzyme
activity with enhanced risk [32].
Endothelial cells express CYPs of the 4A, 2C and 2J
subfamilies [3, 30•]. CYP4A ω-hydrolase produces the
vasoconstrictor 20-HETE, but CYP2C and CYPJ2 epox-
ygenases generate epoxyeicosatrienoic acids (EETs)—5,6-
EET, 11,12-EET, or 14,15-EET—all of which produce
vasodilatation in certain human arteries [3, 30•]. Like other
arachidonic acid metabolites, their vasodilator action is
closely related to EDHF-mediated arteriolar responses
because they stimulate BK channels and cause hyper-
polarizations followed by relaxation [3]. Moreover, they
also facilitate endothelial Ca2+ signaling and likely augment
NO synthesis in an autocrine fashion [33]. In addition, 5,6
EET, 11,12-EET, and 14,15-EET, as well as their degrada-
tion products, dihydroxyeicosatrienoic acids (DHETs), may
produce vasodilatation in a strictly NO-dependent fashion
[33]. This would be explained if EETs/DHETs stimulate
NO formation, either by causing eNOS phosphorylation or
by enhancing Ca2+ signaling following activation of cation
channels of the transient receptor potential gene family
(TRPV4) [24, 29]. Whether these vascular TRPV4 channels
can be treated with drugs is uncertain because of potential
deleterious effects [24, 29]. Importantly, the CYP pathway
must be relevant also for hypertension: clinical data have
demonstrated the ability of CYP products to compensate at
least in part for the loss of NO-mediated dilator responses
in patients with essential hypertension, and soluble epoxide
hydrolase (sEH), an inhibitor of the EET degrading
enzyme, exerts blood pressure–lowering effects in experi-
mental hypertension involving the activation of the renin-
angiotensin system [25]. This blood pressure–lowering
effect was not seen after inhibition of NO synthesis by L-
arginine-methylester (L-NAME), however [33], thus further
showing that augmented EET levels favor NO formation,
which by itself could lower arterial blood pressure. A
specific inhibitor of sEH, AR9281 [25], has been tested in
clinical trials for antihypertensive efficacy and for the
treatment of type 2 diabetes but has failed because of
lack of efficacy. Nevertheless, data from animal studies
show that sEH inhibition or gene deletion could be
effective in pulmonary hypertension or atherosclerosis
and may have protective effects on brain, heart, and
kidneys [25, 34]. The relevance of CYPs and sEH for
cardiovascular disease is supported further by the iden-
tification of polymorphisms (causing reduced enzyme
activities), which have been associated—although not
consistently—with a higher risk for cardiovascular disease,
hypertension, and type 2 diabetes [35]. Considering BK
channels as putative targets of the products of both CYP
and 15-LO, it is noteworthy that “gain of function”
polymorphisms in BK-subunit genes decrease the risk of
hypertension, whereas “loss of function” polymorphisms
increase the risk [36].
Endothelium-dependent Contractions
With aging and in various cardiovascular diseases—
particularly essential (spontaneous) hypertension—
endothelial dysfunction is importantly due to the release
of endothelium-derived contracting factors (EDCFs) that
counteract the effect of endothelium-derived vasodilators.
In healthy blood vessels, the release of EDCFs is tempered
by the presence of NO [37] and EDHFs [38]. The major
EDCFs that contribute to endothelial dysfunction in
hypertension appear to be products of the metabolism of
arachidonic acid. This conclusion is based mainly on data
obtained in arteries of the spontaneously hypertensive rat
(SHR), although it is supported by indirect evidence in
humans [4, 5, 39].
Upon activation of the endothelial cell and the resulting
increase in cytosolic Ca2+ concentration, arachidonic acid is
released from cell membrane phospholipids, whereby phos-
pholipase A2 (PLA2), in both calcium-dependent and
calcium-independent forms, contributes to the process.
Actually, the activation of calcium-dependent PLA2 explains
the calcium dependency of endothelium-dependent contrac-
tions [40•, 41]. Procedures that reduce the increase in
endothelial Ca2+ concentration, such as the administration
of vitamin D3, curtail the occurrence of endothelium-
dependent contractions [42].
The released arachidonic acid is then metabolized by
cyclooxygenases (COX), an enzyme with two major iso-
forms: COX-1 is expressed constitutively and is usually
abundant in all animal and human endothelial cells, whereas
endothelial COX-2 is induced mainly during inflammatory
responses in nearly all animals. In humans, although COX-2
is the predominant contributor to the systemic generation of
prostacyclin, endothelial COX-1 is also a major source of
prostaglandins in both healthy and diseased blood vessels
[43–46]. In arteries of the SHR, there is a marked increase in
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the mRNA expression and protein presence of COX-1,
which underlies the augmented release of EDCFs [43].
The formed unstable endoperoxide (prostaglandin H2,
PGH2) is metabolized further into prostaglandin D2, E2,
F2a, I2 (prostacyclin), and thromboxane A2 by specific
synthases. Depending on the blood vessel studied and the
agonist used to activate the endothelial cells, different
prostaglandins can contribute to endothelium-dependent
contractions. In the SHR aorta, PGH2 and prostacyclin
appear to play the dominant role, mainly because of the
abundance in the endothelial cells of prostacyclin synthase,
compared with the other specific synthases, resulting in the
overwhelming production and release of prostacyclin [43,
47]. The contribution of prostacyclin to EDCF-mediated
responses may seem paradoxical, as one intuitively would
expect the prostanoid to contribute instead to endothelium-
dependent relaxations. Indeed, “specific” prostacyclin IP
receptors are predominantly coupled to the Gs-adenylyl-
cyclase-cyclic adenosine monophosphate (cAMP)-PKA
pathway, and their activation results in vasodilatation.
Patients with a dysfunctional IP receptor mutation show
accelerated atherothrombosis [48••]. A characteristic of the
SHR (and of aged normotensive rats) is that their vascular
smooth muscle cells have lost responsiveness to IP receptor
activation [4, 39].
EDCFs diffuse to the underlying smooth muscle and cause
contraction. When they reach their target, prostaglandins
interact preferentially, but not exclusively, with specific seven
transmembrane domains, G-protein-coupled receptors (DP, EP,
FP, IP, and TP receptors). Of all the prostanoid receptors leading
to activation of vascular smooth muscle cells, TP receptors
appear to be solely responsible for endothelium-dependent
contractions. This conclusion is based on numerous observa-
tions that TP receptor antagonists abolish EDCF-mediated
responses [39, 43, 45, 47]. Thromboxane A2 is by far the
preferential physiological ligand of TP receptors, but endoper-
oxides (PGH2) and higher concentrations of the other
prostaglandins (including prostacyclin, especially in vascular
smooth muscle lacking IP receptor sensitivity), as well as
isoprostanes, activate this receptor with a varying range of
potency. Hence, at least in the SHR, endoperoxides and
prostacyclin play a key role as EDCFs [39, 43]. To judge
from data obtained in the SHR aorta, the TP receptors in
this strain are hyperresponsive to endogenous vasocon-
strictor prostanoids early in the hypertensive process. This
hyperresponsiveness, the IP receptor insensitivity, and the
larger release of endoperoxides and prostacyclin then
explain the preponderance of endothelium-dependent
contractions and the resulting endothelial dysfunction in
the blood vessels (Fig. 2).
Fig. 2 Endothelium-dependent effects of acetylcholine in aorta of Wistar
Kyoto (WKY) rats and spontaneously hypertensive rats (SHR). Left,
Endothelium-dependent relaxations in normotensive WKY rats. Right,
Cyclooxygenase-dependent, endothelium-dependent contractions to ace-
tylcholine in SHR aorta. A23187—calcium ionophore; AA—arachidonic
acid; AC—adenylyl cyclase; ATP—adenosine triphosphate; cAMP—
cyclic adenosine monophosphate; CaV—voltage-activated calcium chan-
nel; cGMP—cyclic guanosinemonophosphate; COX1—cyclooxygenase 1;
eNOS—endothelial nitric oxide synthase; GTP—guanosine triphosphate;
IP—PGI2 receptor; M—muscarinic receptor; O2
•−—superoxide anion;
PGH2—endoperoxide; PGI2—prostacyclin; PGIS—prostacyclin synthase;
PLA2—phospholipase A2; P2Y—putinergic receptor Y2; sGC—soluble
guanylyl cyclase; SR—sarcoplasmic reticulum; TP—TP receptor;
TXA2—thromboxane A2. (From Félétou and Vanhoutte [17]. Used with
permission of The American Physiological Society.)
Curr Hypertens Rep (2010) 12:267–275 273
TP receptor antagonists given in vivo evoke no change
or only minor changes in arterial blood pressure, but
they limit the endothelial dysfunction associated with
hypertension, diabetes, and atherosclerosis; they are
potent antithrombotic agents; and they reduce vascular
inflammation. Therefore, TP receptor antagonists possess
a unique potential to treat cardiovascular complications,
exerting therapeutic benefits beyond those associated
with COX inhibition only [39]. Actually, the addition
of TP antagonism to COX-2 inhibition activity may im-
prove the cardiovascular risk profile of COX-2 inhibitors
[46].
Prostaglandin F2a is also a potent vasoconstrictor;
when administered in mice, it increases arterial blood
pressure. In the hamster aorta, it mediates endothelium-
dependent contractions [45]. Genetic deletion of the FP
receptor, its preferential receptor, reduces blood pressure,
and it delays the occurrence of atherosclerosis in low-
density-lipoprotein (LDL) receptor–deficient mice. Block-
ade of FP receptors may offer a new approach to treating
hypertension and its associated vascular complications
[49].
Conclusions
Endothelial dysfunction, a hallmark of the hypertensive
blood vessel wall, probably reflects the premature aging of
the intima exposed to the chronic increase in arterial blood
pressure. It is caused by complex changes in the balance
between endothelium-dependent vasodilator and vasocon-
strictor signals. The release of NO and the occurrence of
endothelium-dependent hyperpolarizations can be endan-
gered. As a result, the production of vasoconstrictor
prostanoids (mainly endoperoxides and prostacyclin) is
unleashed. Augmenting the bioavailability of NO, favoring
the occurrence of EDHF-mediated responses, and prevent-
ing the release or action of EDCFs all can contribute to
restoring proper endothelial function and thus can delay the
appearance of vascular complications resulting from the
hypertensive process.
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